Allogeneic Transplantation
Lymphoma Trials (B- and T-cell)
COMIRB: 21-2578
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
PI: Manali Kamdar
Eligibility: Ages ≥ 16; Relapsed or refractory aggressive B-cell NHL; ECOG of 0 or 1
COMIRB: 22-0939
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
PI: Manali Kamdar
Eligibility: Ages ≥ 18; ECOG of ≤2
COMIRB: 23-0056
A Phase 3, Open-Label, Randomized Study of A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
PI: Manali Kamdar
Eligibility: Ages ≥ 18; Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasm
COMIRB: 24-0458
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a fenretinide phospholipid suspension (12.5 mg/mL) for Intravenous Infusion
Principal Investigator: Brad Haverkos
Eligibility: Ages ≥ 18; ECOG of 0-1; diagnosed CTCL or Nodal TCL
COMIRB: 24-2065
Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults
Principal Investigator: Sarah Milgrom
Newly diagnosed patients with Stage I and II Classic Hodgkins Lymphoma
COMIRB: 24-2331
Phase 3 Study Comparing the Combination of Beleodaq-CHOP Regimen Alone
Principal Investigator: Bradley Haverkos
Newly diagnosed patients with Peripheral T-cell Lymphoma
COMIRB: 25-0024
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
PI: Manali Kamdar
Eligibility: Participants must have a histologically confirmed diagnosis of Classic Follicular Lymphoma (cFL). cFL was previously categorized as Grade 1-3A per WHO-HAEM4R, but grading of classic FL is no longer mandatory. *Please see other eligibility details
COMIRB: 25-1099
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma
PI: Brad Haverkos
Eligibility criteria are described in the link below.
COMIRB: 25-2042
A Phase 3, randomized controlled trial of Rondecabtagene autoleucel, an autologous, dual-targeting CD 19/CD20 CAR-T cell product candidate, vs. Investigator's choice of CD19 CAR-T cell therapy in patients with relapsed or refractory large b-cell lymphoma in the second-line setting (PINACLE-H2H)
PI: Manali Kamdar
Eligibility criteria are described in the link below.
COMIRB: 25-2042
BAF_FRontier-1, A First-in-Human, Phase 1Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody, in Adult Participants with Previously Treated B-cell Malignancies
PI: Manali Kamdar
Eligibility criteria are described in the link below.
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.